Biotech industry experiencing growth due to trends like AI-driven drug discovery and personalized medicine.

From Yahoo Finance: 2025-04-02 09:47:00

The biotech industry is on the rise with a projected 13% global market growth from $483.0 billion in 2024 to $546.0 billion in 2025. Factors such as AI-driven drug discovery and personalized medicine are driving this growth, attracting investor interest and accelerating drug development.

Lower interest rates are expected to boost biotech companies by increasing available cash for R&D and attracting venture capital. The global biotechnology sector is experiencing transformational growth in 2025, with key trends like genetic engineering, synthetic biology, AI-driven drug discovery, and RNA therapeutics shaping the industry.

Biotech therapies are making significant strides, with CRISPR-Cas9 treatments, mRNA vaccines, and regenerative medicine leading the way. The sector continues to thrive with groundbreaking treatments like Imdelltra and zanzalintinib, with potential sales reaching billions by 2030 and beyond.

Argenx SE (NASDAQ:ARGX) ranks fifth among the most profitable biotech stocks, specializing in antibody-based therapies for autoimmune diseases and cancer. The company delivered strong financial results in Q4 2024 and plans for sustained growth with ambitious goals for treating patients and progressing pipeline candidates.

In 2025, Argenx SE (NASDAQ:ARGX) expects to achieve profitability with strategic initiatives and regulatory progress. Despite its potential, AI stocks are seen as holding greater promise for higher returns within a shorter timeframe. Investors looking for alternative opportunities can explore undervalued AI stocks for potential gains.

Read more: Is Argenx SE (ARGX) The Most Profitable Biotech Stock To Buy Right Now?